FAST4WARD: implications for the clinician

Int J Clin Pract. 2009 Jul;63(7):986-8. doi: 10.1111/j.1742-1241.2009.02095.x.
No abstract available

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Certolizumab Pegol
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Middle Aged
  • Multicenter Studies as Topic
  • Polyethylene Glycols / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin Fab Fragments
  • Tumor Necrosis Factor-alpha
  • Polyethylene Glycols
  • Certolizumab Pegol